T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRTA
2801
Strata Critical Medical Inc
SRTA
$525M
| $68K | ﹤0.01% |
19,377
+3,556
| +22% | +$11.9K |
|
|
WW
2802
DELISTED
WW International
WW
| $68K | ﹤0.01% |
57,800
+12,326
| +27% | +$20.5K |
|
2803
Intellicheck
IDN
$74.7M
| $67K | ﹤0.01% |
19,500
| – | – |
|
2804
LanzaTech
LNZA
$67.1M
| $67K | ﹤0.01% |
+359
| New | +$91.5K |
|
|
TEAD
2805
Teads Holding Co
TEAD
$63.8M
| $67K | ﹤0.01% |
13,350
+2,762
| +26% | +$12.3K |
|
|
ONL
2806
Orion Office REIT
ONL
$160M
| $67K | ﹤0.01% |
18,453
+879
| +5% | +$3.01K |
|
2807
Zevra Therapeutics
ZVRA
$670M
| $67K | ﹤0.01% |
13,599
+2,588
| +24% | +$12.3K |
|
2808
Angi Inc
ANGI
$187M
| $66K | ﹤0.01% |
3,400
| – | – |
|
2809
Biomea Fusion
BMEA
$95M
| $66K | ﹤0.01% |
14,537
-163,065
| -92% | -$1.66M |
|
2810
Coherus Oncology
CHRS
$176M
| $66K | ﹤0.01% |
37,748
+6,897
| +22% | +$13.9K |
|
2811
ALX Oncology
ALXO
$274M
| $65K | ﹤0.01% |
10,622
-222,147
| -95% | -$2.73M |
|
2812
Codexis
CDXS
$177M
| $65K | ﹤0.01% |
20,794
| – | – |
|
|
PPTA
2813
Perpetua Resources
PPTA
$3.08B
| $64K | ﹤0.01% |
12,297
+248
| +2% | +$1.47K |
|
2814
Radiant Logistics
RLGT
$406M
| $64K | ﹤0.01% |
11,113
+1,067
| +11% | +$5.56K |
|
|
QVCGA
2815
DELISTED
QVC Group Inc Series A
QVCGA
| $64K | ﹤0.01% |
2,025
| – | – |
|
2816
Purple Innovation
PRPL
$29.2M
| $63K | ﹤0.01% |
2,400
| – | – |
|
2817
Quantum-Si Incorporated
QSI
$190M
| $63K | ﹤0.01% |
59,727
| – | – |
|
2818
Rackspace Technology
RXT
$1.08B
| $63K | ﹤0.01% |
20,861
+4,046
| +24% | +$8.12K |
|
2819
W&T Offshore
WTI
$548M
| $63K | ﹤0.01% |
29,409
| – | – |
|
|
PSTX
2820
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $63K | ﹤0.01% |
21,471
+2,654
| +14% | +$7.26K |
|
2821
Holley
HLLY
$364M
| $62K | ﹤0.01% |
17,310
+3,263
| +23% | +$12.7K |
|
|
KLRS
2822
Kalaris Therapeutics
KLRS
$95.2M
| $62K | ﹤0.01% |
3,735
-525
| -12% | -$9.27K |
|
|
AMRN
2823
Amarin Corp
AMRN
$300M
| $60K | ﹤0.01% |
4,387
| – | – |
|
2824
Destination XL Group
DXLG
$34.2M
| $60K | ﹤0.01% |
16,314
| – | – |
|
|
PHLT
2825
DELISTED
Performant Healthcare Inc
PHLT
| $59K | ﹤0.01% |
20,304
+2,289
| +13% | +$6.57K |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.